Juno Therapeutics (JUNO) Misses Q1 EPS by 26c

Juno Therapeutics (NASDAQ: JUNO) reported Q1 EPS of ($0.78), $0.26 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $4.65 million.

Juno expects 2016 cash burn, excluding cash inflows or outflows from business development activities, to be between $220 million and $250 million.

• Operating burn estimated to be between $170 million and $195 million.
• Capital expenditures estimated to be between $40 million and $55 million, the vast majority of which are related to one-time infrastructure build-outs.

For earnings history and earnings-related data on Juno Therapeutics (JUNO) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• VNET Group (VNET) Misses Q2 EPS by 164c
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance